Company Description
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
It developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
The company’s pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrevimab, that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19.
It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies.
The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022.
Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2020 |
| IPO Date | Aug 6, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | William Duke |
Contact Details
Address: 1601 Trapelo Road, Suite 178 Waltham, Massachusetts 02451 United States | |
| Phone | 781 819 0080 |
| Website | invivyd.com |
Stock Details
| Ticker Symbol | IVVD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001832038 |
| CUSIP Number | 00534A102 |
| ISIN Number | US00534A1025 |
| Employer ID | 85-1403134 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert D. Allen Ph.D. | Chief Scientific Officer |
| Jill Andersen J.D. | Chief Legal Officer and Corporate Secretary |
| William E. Duke Jr., M.B.A. | Chief Financial Officer and Principal Executive Officer |
| Scott Young | Senior Vice President of Investor Relations and Corporate Communications |
| Julie Green M.B.A. | Chief Human Resources Officer |
| Dr. Mark A. Wingertzahn Ph.D. | Senior Vice President of Clinical Development and Medical Affairs |
| Timothy Lee | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 10-K | Annual Report |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Feb 3, 2025 | 8-K | Current Report |
| Jan 27, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 8-K | Current Report |
| Dec 27, 2024 | 8-K | Current Report |